Green Thumb Industries (GTBIF) Cost of Revenue (2019 - 2026)
Green Thumb Industries (GTBIF) posted Cost of Revenue of $156.5 million for Q1 2026, down 7.8% on a QoQ basis from $169.8 million in Q4 2025, and up 14.88% year-over-year from $136.3 million in Q1 2025.
Green Thumb Industries (GTBIF) Cost of Revenue (2019 - 2026) Analysis & Trends
Green Thumb Industries' Cost of Revenue history runs 8 years deep, the most recent figure standing at $156.5 million for Q1 2026.
- Quarterly Cost of Revenue rose 14.88% year-over-year to $156.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $620.7 million (up 14.64% YoY) and the FY2025 annual result came in at $600.4 million, up 12.01% from the prior year.
- Cost of Revenue was $156.5 million for Q1 2026 at Green Thumb Industries, down from $169.8 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $169.8 million in Q4 2025 and bottomed at $119.7 million in Q1 2022.
- A 5-year average of $137.3 million and a median of $135.5 million in 2023 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2022 — Cost of Revenue soared 43.19% — and 2024, when it slipped 1.64%.
- Green Thumb Industries' Cost of Revenue stood at $135.3 million in 2022, then increased by 0.19% to $135.5 million in 2023, then grew by 0.52% to $136.3 million in 2024, then climbed by 24.62% to $169.8 million in 2025, then fell by 7.8% to $156.5 million in 2026.
- Business Quant data shows GTBIF's Cost of Revenue at $156.5 million in Q1 2026, $169.8 million in Q4 2025, and $147.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Green Thumb Industries | 1.63 Bn | 1.29 Bn | 143.65 Mn | 156.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 156.55 Mn |
| Mar 31, 2026 | 156.55 Mn |
| Dec 31, 2025 | 169.79 Mn |
| Dec 31, 2025 | 169.79 Mn |
| Sep 30, 2025 | 147.34 Mn |
| Sep 30, 2025 | 147.34 Mn |
| Jun 30, 2025 | 147.00 Mn |
| Jun 30, 2025 | 147.00 Mn |
| Mar 31, 2025 | 136.27 Mn |
| Mar 31, 2025 | 136.27 Mn |
| Dec 31, 2024 | 136.25 Mn |
| Dec 31, 2024 | 136.25 Mn |
| Sep 30, 2024 | 139.27 Mn |
| Sep 30, 2024 | 139.27 Mn |
| Jun 30, 2024 | 129.63 Mn |
| Jun 30, 2024 | 129.63 Mn |
| Mar 31, 2024 | 130.88 Mn |
| Mar 31, 2024 | 130.88 Mn |
| Dec 31, 2023 | 135.54 Mn |
| Dec 31, 2023 | 135.54 Mn |